FI61807B - Foerfarande foer stabilisering av meningokockpolysackarid - Google Patents
Foerfarande foer stabilisering av meningokockpolysackarid Download PDFInfo
- Publication number
- FI61807B FI61807B FI783250A FI783250A FI61807B FI 61807 B FI61807 B FI 61807B FI 783250 A FI783250 A FI 783250A FI 783250 A FI783250 A FI 783250A FI 61807 B FI61807 B FI 61807B
- Authority
- FI
- Finland
- Prior art keywords
- meningococcal
- polysaccharide
- meningokockpolysackarid
- lactose
- foerfarande foer
- Prior art date
Links
- 150000004676 glycans Chemical class 0.000 description 24
- 229920001282 polysaccharide Polymers 0.000 description 24
- 239000005017 polysaccharide Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 229960005486 vaccine Drugs 0.000 description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 3
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960005037 meningococcal vaccines Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2748132 | 1977-10-27 | ||
| DE19772748132 DE2748132A1 (de) | 1977-10-27 | 1977-10-27 | Stabilisator fuer polysaccharid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI783250A7 FI783250A7 (fi) | 1979-04-28 |
| FI61807B true FI61807B (fi) | 1982-06-30 |
Family
ID=6022367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI783250A FI61807B (fi) | 1977-10-27 | 1978-10-25 | Foerfarande foer stabilisering av meningokockpolysackarid |
Country Status (11)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| US4451446A (en) * | 1982-03-04 | 1984-05-29 | Smithkline-Rit | Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them |
| GB2187191B (en) * | 1984-01-30 | 1989-11-01 | Quadrant Bioresources Ltd | Protection of proteins and the like |
| US4931385A (en) * | 1985-06-24 | 1990-06-05 | Hygeia Sciences, Incorporated | Enzyme immunoassays and immunologic reagents |
| JPH0779694B2 (ja) * | 1985-07-09 | 1995-08-30 | カドラント バイオリソ−シズ リミテツド | 蛋白質および同類品の保護 |
| US4868108A (en) * | 1985-12-12 | 1989-09-19 | Hygeia Sciences, Incorporated | Multiple-antibody detection of antigen |
| US4762857A (en) * | 1986-05-30 | 1988-08-09 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
| US4678812A (en) * | 1986-05-30 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Trehalose as stabilizer and tableting excipient |
| US5102788A (en) * | 1988-11-21 | 1992-04-07 | Hygeia Sciences, Inc. | Immunoassay including lyophilized reactant mixture |
| JPH03208485A (ja) * | 1990-01-11 | 1991-09-11 | Matsushita Electric Ind Co Ltd | 文字放送受信装置 |
| US5200399A (en) * | 1990-09-14 | 1993-04-06 | Boyce Thompson Institute For Plant Research, Inc. | Method of protecting biological materials from destructive reactions in the dry state |
| US6509006B1 (en) | 1992-07-08 | 2003-01-21 | Inhale Therapeutic Systems, Inc. | Devices compositions and methods for the pulmonary delivery of aerosolized medicaments |
| US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US7448375B2 (en) * | 1993-01-29 | 2008-11-11 | Aradigm Corporation | Method of treating diabetes mellitus in a patient |
| US6024090A (en) * | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| ES2316917T3 (es) * | 1994-03-07 | 2009-04-16 | Nektar Therapeutics | Metodos y composiciones para suministro pulmonar de insulina. |
| CN1188171C (zh) | 1994-06-02 | 2005-02-09 | 廓德伦特控股剑桥有限公司 | 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物 |
| GB9508691D0 (en) * | 1995-04-28 | 1995-06-14 | Pafra Ltd | Stable compositions |
| US5876992A (en) * | 1996-07-03 | 1999-03-02 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| FR2791895B1 (fr) * | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| PT1440082E (pt) | 2001-10-22 | 2011-12-07 | Dompe Spa | Processamento de fluidos supercríticos: preparação de micropartículas de proteína e sua estabilização |
| PT1490409E (pt) * | 2002-03-26 | 2009-04-03 | Novartis Vaccines & Diagnostic | Sacáridos modificados possuindo uma estabilidade melhorada em água |
| US20030124139A1 (en) * | 2002-11-20 | 2003-07-03 | Irina Esikova | Compositions and methods for stabilizing biological molecules upon lyophilization |
| PL1858488T5 (pl) | 2005-03-14 | 2024-01-03 | Wyeth Llc | Kompozycje tygecykliny i sposoby wytwarzania |
| EP3009146B1 (en) * | 2005-06-27 | 2021-10-20 | Pfizer Ireland Pharmaceuticals | Immunogenic composition |
| GB0612854D0 (en) * | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| WO2010144682A1 (en) | 2009-06-12 | 2010-12-16 | Micronics, Inc. | Rehydratable matrices for dry storage of taq polymerase in a microfluidic device |
| AU2010258716B2 (en) | 2009-06-12 | 2015-11-12 | Revvity Health Sciences, Inc. | Compositions and methods for dehydrated storage of on-board reagents in microfluidic devices |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2908614A (en) * | 1954-08-10 | 1959-10-13 | Glaxo Lab Ltd | Use of dextran in freeze-drying process |
| US3135663A (en) * | 1960-06-28 | 1964-06-02 | Glaxo Group Ltd | Vaccines |
| GB995362A (en) * | 1962-05-11 | 1965-06-16 | Smith Kline French Lab | Improvements in or relating to freeze-drying biological material |
| DE1183629B (de) * | 1962-12-21 | 1964-12-17 | Behringwerke Ag | Verfahren zur Stabilisierung biologisch aktiven Materials |
| US3567585A (en) * | 1963-07-12 | 1971-03-02 | Ciba Geigy Corp | Process for obtaining bcg-cultures |
| DE1617350C3 (de) * | 1967-06-22 | 1979-09-06 | Behringwerke Ag, 3550 Marburg | Verfahren zur Inaktivierung von biologischem Material |
| US3532790A (en) * | 1968-02-23 | 1970-10-06 | Canadian Patents Dev | Somatic antigen vaccines from lysed inactivated bacteria and process for producing them |
| FR7461M (enrdf_load_stackoverflow) * | 1968-06-19 | 1970-01-05 | ||
| GB1218277A (en) * | 1968-08-20 | 1971-01-06 | Miles Lab | Dry water-dispersible aluminium hydroxide gels |
| US3577527A (en) * | 1969-01-27 | 1971-05-04 | Us Navy | Neisseria meningitidis antigen |
| US3599150A (en) * | 1969-08-01 | 1971-08-10 | Miles Lab | Stabilized aluminum hydroxide suspensions |
| US3636192A (en) * | 1970-01-13 | 1972-01-18 | Us Army | Meningococcal polysaccharide vaccines |
| US3859434A (en) * | 1973-01-08 | 1975-01-07 | Canadian Patents Dev | Meningococcal antigens |
-
1977
- 1977-10-27 DE DE19772748132 patent/DE2748132A1/de active Granted
-
1978
- 1978-10-21 ES ES474412A patent/ES474412A1/es not_active Expired
- 1978-10-25 FI FI783250A patent/FI61807B/fi not_active Application Discontinuation
- 1978-10-25 SE SE7811083A patent/SE447700B/sv not_active IP Right Cessation
- 1978-10-25 US US05/954,461 patent/US4206200A/en not_active Expired - Lifetime
- 1978-10-26 CA CA314,311A patent/CA1113861A/en not_active Expired
- 1978-10-26 DK DK477278A patent/DK158006C/da not_active IP Right Cessation
- 1978-10-27 GB GB7842190A patent/GB2009198B/en not_active Expired
- 1978-10-27 BE BE191411A patent/BE871612A/xx not_active IP Right Cessation
- 1978-10-27 FR FR7830616A patent/FR2406999A1/fr active Granted
- 1978-10-27 JP JP13173878A patent/JPS5470422A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| BE871612A (fr) | 1979-04-27 |
| FR2406999A1 (fr) | 1979-05-25 |
| ES474412A1 (es) | 1979-04-16 |
| SE7811083L (sv) | 1979-04-28 |
| DE2748132C2 (enrdf_load_stackoverflow) | 1989-04-06 |
| DK477278A (da) | 1979-04-28 |
| JPS5470422A (en) | 1979-06-06 |
| US4206200A (en) | 1980-06-03 |
| FI783250A7 (fi) | 1979-04-28 |
| GB2009198B (en) | 1982-10-27 |
| DK158006C (da) | 1990-08-06 |
| CA1113861A (en) | 1981-12-08 |
| FR2406999B1 (enrdf_load_stackoverflow) | 1982-11-12 |
| JPS6310686B2 (enrdf_load_stackoverflow) | 1988-03-08 |
| DE2748132A1 (de) | 1979-05-03 |
| DK158006B (da) | 1990-03-12 |
| SE447700B (sv) | 1986-12-08 |
| GB2009198A (en) | 1979-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI61807B (fi) | Foerfarande foer stabilisering av meningokockpolysackarid | |
| FI79024C (fi) | Foerfarande foer framstaellning av haemophilus influenzae b-polysackaridexotoxoidkonjugatvaccin. | |
| EP0130619B1 (en) | Hepatitis b vaccine and method for its preparation | |
| KR930010623B1 (ko) | 백금계 항암화합물의 안정한 동결건조물의 제조방법 | |
| US4460575A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
| DE69620271T2 (de) | Polyribosylribitol-phosphat enthaltende Haemophilus-influenzae-Typ-b-Impfstoffzubereitung und Verfahren zur deren Herstellung | |
| DE3881281T2 (de) | Stabilisierter attenuierter lebender impfstoff und seine herstellung. | |
| CA1223207A (en) | Gamma interferon composition | |
| JPH11503719A (ja) | 乾燥組成物 | |
| KR20090007588A (ko) | 니코틴-담체 백신 제제 | |
| US5424287A (en) | Extract of bacterial macromolecules, a process for its preparation and a pharmaceutical composition containing the same | |
| UA77295C2 (en) | Liquid preparation comprising camptothecin derivative and pharmaceutical composition produced by freeze-drying | |
| JPH0236236B2 (enrdf_load_stackoverflow) | ||
| IE47226B1 (en) | Freeze-dried meningococcus polysaccharides | |
| IL41902A (en) | Immunogenic substance,its production,vaccine preparations containing it and their preparation | |
| DD299213A7 (de) | Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung | |
| EP0702960A1 (en) | Liquid globulin composition for intravenous injection, process for producing the same, and method of inhibiting globulin dimer increase in said composition | |
| KR870000237B1 (ko) | 세라펩타제를 안정화 시키는 방법 | |
| JPH07157431A (ja) | 安定なプロスタグランジンｅ製剤 | |
| US20040033550A1 (en) | Method of isolating biologically active fraction containing clinically acceptable native S-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides | |
| IL30448A (en) | Protein metal chelate composition stabilized with saccharide,and preparation thereof | |
| US4954522A (en) | Lyophilized preparation of platinum compound | |
| JPH08509374A (ja) | 生存可能な細菌 | |
| EP0036514B1 (de) | Verwendung eines aus Blutserum gewonnenen Wirkstoffes zur Stabilisierung von Prostaglandinen | |
| JPH0314291B2 (enrdf_load_stackoverflow) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |
Owner name: BEHRINGWERKE AKTIENGESELLSCHAFT |